Cargando…
Sildenafil for the Treatment of Alzheimer’s Disease: A Systematic Review
Nitric oxide/cyclic guanosine monophosphate (cGMP) signaling is compromised in Alzheimer’s disease (AD), and phosphodiesterase 5 (PDE5), which degrades cGMP, is upregulated. Sildenafil inhibits PDE5 and increases cGMP levels. Integrating previous findings, we determine that most doses of sildenafil...
Autor principal: | Sanders, Owen |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
IOS Press
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7242821/ https://www.ncbi.nlm.nih.gov/pubmed/32467879 http://dx.doi.org/10.3233/ADR-200166 |
Ejemplares similares
-
Sildenafil in the treatment of pulmonary hypertension
por: Barnett, Christopher F, et al.
Publicado: (2006) -
Phosphodiesterase Inhibitors for Alzheimer’s Disease: A Systematic Review of Clinical Trials and Epidemiology with a Mechanistic Rationale
por: Sanders, Owen, et al.
Publicado: (2020) -
Sildenafil does not reliably improve exercise performance in hypoxia: a systematic review
por: Carter, Eric Alexander, et al.
Publicado: (2019) -
A Systematic Review of Sildenafil Mortality Through the Years
por: Al Ibrahim, Abdullah H, et al.
Publicado: (2022) -
Sildenafil in Infants and Children
por: Simonca, Larisa, et al.
Publicado: (2017)